Search - tctmd.com

Displaying 1 - 20 of 20

Sort: Relevancy | Date

News Daily News

Year in Review: Top Prevention Stories of 2025

Michael O'Riordan

December 24, 2025

News Daily News

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Michael O'Riordan

July 14, 2025

News Daily News

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Michael O'Riordan

April 22, 2025

News Conference News AHA 2024

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Michael O'Riordan

November 18, 2024

News Conference News ACC 2023

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Michael O'Riordan

March 04, 2023

News Daily News

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Michael O'Riordan

January 05, 2023

News Features

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Michael O'Riordan

August 15, 2022

News Daily News

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

Michael O'Riordan

August 11, 2022

News Conference News ACC 2022

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

Michael O'Riordan

April 03, 2022

News Features

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

Michael O'Riordan

April 07, 2020

News Daily News

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

Michael O'Riordan

April 25, 2018

News Daily News

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

Michael O'Riordan

April 24, 2018

News Features

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Todd Neale

September 15, 2017

News Daily News

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

Michael O'Riordan

July 25, 2017

News Features

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

Michael O'Riordan

May 23, 2017

News Conference News ACC 2017

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Michael O'Riordan

March 17, 2017

News Daily News

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

Michael O'Riordan

March 13, 2017

News Daily News

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

Michael O'Riordan

November 09, 2016

News Conference News ESC 2014

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

Todd Neale

September 02, 2014

News Conference News ACC 2014

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

Jason Kahn

March 31, 2014

Advertisement

Year in Review: Top Prevention Stories of 2025

No Clarity on Colchicine: Two Meta-analyses Spark Debate on Drug’s Merits

Early Combo Therapy With Ezetimibe Lowers MACE Risk After MI

Two Lp(a)-Lowering Therapies Clear Bar in KRAKEN and ALPACAR-360

Clear CVD Benefit With Bempedoic Acid: CLEAR Outcomes

Study Alleges Mortality Miscount in FOURIER Trial; TIMI Group Disagrees

Novel Targets, Gene Edits, and Vaccines: Is a ‘Golden Era’ Dawning for ASCVD?

Genetic Study Hints at Cognitive Impact of Statins, but Experts Urge Caution

APOLLO: Novel siRNA Injectable Cuts Lp(a) by Nearly 100% in Small Study

‘Salvage What We Can’: Cardiology Clinical Trials in Turmoil Amid COVID-19

FDA Advisory Panel Says Celecoxib Is as Safe for Heart as Ibuprofen and Naproxen

FDA Advisors Take Fresh Look at Celecoxib Safety as PRECISION Aspirin Analysis Unveiled

COMPASS: All Signs Point to Big Impact in CAD and PAD, Experts Predict

Staying on Statins After an Adverse Event Lowers Risks of Death, MI or Stroke

How Low Can You Go? Concerns Over Aggressive LDL Lowering Eased as PCSK9 Evidence Mounts

FOURIER: Evolocumab Reduces Risk of CVD Events by 15% Compared With Placebo

Statin-Intolerant Patients Have Significantly Worse Prognosis After MI

MILANO-PILOT Falters, Effectively Ending the ApoA-1 Milano Saga

IBIS-4: High-Dose Statin Therapy May Reverse Atherosclerosis in STEMI

GIPS-III: Diabetes Drug Metformin Not Cardioprotective in Nondiabetic STEMI Patients After Primary PCI

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content